Clinical Trial Update: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

Status update on a Phase 1/2 trial evaluating Avutometinib (VS-6766) plus Adagrasib in KRAS G12C non-small cell lung cancer. The study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• Avutometinib (avutometinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING